TF rs3811647 variant alters serum transferrin and iron transport

The TF rs3811647 gene variant is a major genetic modifier of systemic iron regulation, directly influencing transferrin concentrations and the body's iron transport dynamics.

Clinical and genetic evidence

• Genetic modulation of transferrin: Large-scale genome-wide association studies (GWAS) identify the TF rs3811647 variant (located in intron 11) as a major quantitative trait locus for serum transferrin. Together with HFE variants, TF loci explain approximately 40% of the genetic variance in transferrin levels.
• Genotype-specific effects: Research demonstrates a strong, allele-specific effect where homozygotes for the AA genotype exhibit approximately 21% higher serum transferrin concentrations compared to GG homozygotes.

Mechanistic insights into iron binding

• Altered binding capacity: Because total iron-binding capacity (TIBC) and unsaturated iron-binding capacity (UIBC) are chemically proportional to circulating transferrin levels, the rs3811647 variant directly shapes systemic iron transport.
• Saturation dynamics: Carriers of the AA genotype present with a 24% increase in UIBC and a 25% reduction in transferrin saturation (TSAT) compared to GG carriers.
• Safe iron transport: By increasing or decreasing the availability of unoccupied transferrin binding sites, this genetic variant changes how much circulating iron can be safely bound to transferrin, modulating protection against toxic, unbound circulating iron.

Bottom line

• The TF rs3811647 variant is a robust quantitative modifier of serum transferrin concentrations. It directly dictates total iron-binding capacity and transferrin saturation levels, determining how much circulating iron is safely bound and transported throughout the body.